Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/3/2024 | $48.00 | Outperform | Oppenheimer |
| 7/26/2024 | $58.00 | Outperform | Robert W. Baird |
| 6/27/2024 | Overweight | Cantor Fitzgerald | |
| 5/16/2024 | $40.00 | Buy | H.C. Wainwright |
| 2/15/2024 | $44.00 | Buy | Stifel |
| 12/26/2023 | $22.00 | Buy | Jefferies |
| 11/22/2023 | $23.00 | Outperform | Wedbush |
| 10/30/2023 | $45.00 | Buy | Guggenheim |
10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
RW - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
3 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
Oppenheimer initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $48.00
Robert W. Baird initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $58.00
Cantor Fitzgerald initiated coverage of Dianthus Therapeutics with a rating of Overweight
Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating.
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24 Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 Approximately $343 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmu
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024: Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MAJefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London7th Annual Evercore HealthCONx Conference on December 4 at 1
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia. DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for p
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)